Results 61 to 70 of about 26,612 (257)

A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4

open access: yesJournal of Pharmacological Sciences, 2019
Dipeptidyl peptidase-4 (DPP-4) inhibitors not only improve impaired glucose tolerance in diabetes, but also have pleiotropic extra-pancreatic effects such as preconditioning effect for myocardial ischemia-reperfusion injury.
Takehiro Yamaguchi   +12 more
doaj   +1 more source

Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes

open access: yesWorld Journal of Diabetes, 2010
The addition of the dipeptidyl peptidase-4 (DDP-4) inhibitor has been reported to achieve greater improvements in glucose metabolism with fewer adverse events compared to increasing the metformin dose in type 2 diabetic patients. We present a patient with steroid-induced diabetes whose blood glucose levels were ameliorated by the use of the DPP-4 ...
Hidekatsu, Yanai   +4 more
openaire   +2 more sources

Bromelain as the enzyme of the future: A global bibliometric mapping of its applications and emerging trends

open access: yesJournal of the Science of Food and Agriculture, EarlyView.
Abstract INTRODUCTION Bromelain, a complex mixture of proteolytic enzymes primarily extracted from plants of the Bromeliaceae family, has gained prominence because of its broad industrial applicability, particularly in the food, pharmaceutical and cosmetic sectors.
Genésio José da Silva Neto   +6 more
wiley   +1 more source

Correlations Among Glycemia and Glucose Variability, Thyroid Hormones, and Albuminuria in Patients With Type 2 Diabetes Mellitus

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Hyperglycemia, glucose fluctuations, and thyroid dysfunction contribute to the progression of diabetic nephropathy. This study aimed to investigate the associations of glycemia, glucose variability, and thyroid hormones with albuminuria in patients with type 2 diabetes mellitus (T2DM). In total, 451 T2DM patients were included.
Na Luo   +12 more
wiley   +1 more source

Plasmepsins as Antimalarial Drug Targets—Then, Now, and the Future

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Malaria is a devastating disease caused by Plasmodium parasites. Plasmodium parasites express ten cathepsin D‐like aspartyl proteases, called plasmepsins (PMs). These PMs have diverse roles fulfill diverse functions throughout the parasite's lifecycle, though several exhibit functional redundancies. Among them, PMV, PMIV, and PMX are essential
Brad E. Sleebs
wiley   +1 more source

Sulfonylurea prescription patterns in elderly patients with type 2 diabetes mellitus: A comprehensive analysis of real‐world data from pharmacies in Japan

open access: yesJournal of Diabetes Investigation
Aims/Introduction The study aim was to investigate sulfonylurea prescription patterns in elderly patients (age ≥65 years) with type 2 diabetes mellitus in Japan. Sulfonylurea use among older adults has been insufficiently examined, despite the associated
Michiko Yamazaki   +6 more
doaj   +1 more source

Late INa as a Therapeutic Target: New Strategies, Computational Modelling, Drug Development, and Clinical Translation

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT The Nav1.5 channel, a major isoform of voltage‐gated sodium ion channel, is mainly found in ventricular cardiomyocytes, playing a key role in generating essential cardiac action potentials for normal heart rhythms. Mutations in Nav1.5 have been associated with severe heart conditions such as long QT syndrome, Brugada syndrome, cardiac ...
Arkapravo Chattopadhyay   +3 more
wiley   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

open access: yesObesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu   +13 more
wiley   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

open access: yesObesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone   +3 more
wiley   +1 more source

Time to exacerbation of heart failure is longer in Malaysian population on dipeptidyl peptidase-4 inhibitor

open access: yesHeart India, 2017
Context: Diabetes mellitus is a recognized risk factor for heart failure. Dipeptidyl peptidase-4 inhibitors (DPP4i) are used in patients with diabetes largely due to its efficacy in glycated hemoglobin (HbA1c) reduction, neutral weight effect, and lower ...
J Hasan   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy